Board of Directors

Barry Bloom (Chair)

PhD, Distinguished University Service Professor, Joan L. and Julius H. Jacobson Professor of Public Health, Harvard University, USA

A leading scientist in the areas of infectious diseases, vaccines, and global health and former consultant to the White House, Dr. Barry Bloom continues to pursue an active interest in bench science as the principal investigator of a laboratory researching the immune response to tuberculosis, a disease that claims more than two million lives each year. He has been extensively involved with the World Health Organization (WHO) for more than 40 years. He is currently Chair of the Technical and Research Advisory Committee to the Global Program on Malaria at WHO and has been a member of the Technical Advisory Committee of the UNDP/World Bank/WHO Special Program for Research and Training in Leprosy and Tuberculosis Research, and Tropical Diseases. Dr. Bloom serves on the editorial board of the Bulletin of the World Health Organization, the Ellison Medical Foundation Scientific Advisory Board and the Welcome Trust Pathogens, Immunology and Population Health Strategy Committee. He is on the Scientific Advisory Board of the Earth Institute at Columbia University and the Advisory Council of the Paul G. Rogers Society for Global Health Research. Dr. Bloom was the founding chair of the board of trustees for the International Vaccine Institute in South Korea, which is devoted to promoting vaccine development for children in the developing world. He has chaired the Vaccine Advisory Committee of UNAIDS, where he played a critical role in the debate surrounding the ethics of AIDS vaccine trials. He was also a member of the US AIDS Research Committee. Dr. Bloom came to HSPH to serve as Dean of the Faculty in 1998. He stepped down December 31, 2008 and is currently a Harvard University Distinguished Service Professor at HSPH. In his capacity as Dean, he served as Secretary Treasurer for the Association of Schools of Public Health (ASPH). Prior to that he served as chairman of the Department of Microbiology and Immunology at the Albert Einstein College of Medicine from 1978 to 1990, the year in which he became an Investigator of the Howard Hughes Medical Institute, where he also served on the National Advisory Board. In 1978, he was a consultant to the White House on international health policy. Dr. Bloom holds a bachelor’s degree in biology and an honorary D.Sc. from Amherst College and a Ph.D. in immunology from Rockefeller University.

Yixin Zeng

MD, PhD, President of Peking Union Medical College, Beijing, China

Dr. Zeng Yixin is the current president of Peking Union Medical College. He is also the director of the State Key Laboratory of Oncology in Southern China Oncology in Southern China, and the president at Sun Yat-sen University Cancer Center. His major research interests focuses on the pathogenesis of nasopharyngeal carcinoma and gene therapy of cancer. Since 1997, he has been awarded many research grants from the NIH, China National Science Foundation, China “863 Program” and “973 Program”. His research has been published in various scientific journals such as “Nature” and “Nature Genetics”. He has won several national and international awards including the second class prize of the National Nature Science Award in China, the He-Liang-He-Li Fund Award, and the Grand Silver Medal from Karolinska Institute. Dr. Zeng was elected as the academician of Chinese Academy of Sciences in 2005 and the fellow of Third World Academy of Sciences in 2008. He also serves as the vice director of the Deepening China Healthcare Reform Expert Panel of the State Council and the vice chairman of Chinese Anti-cancer Association. He serves on the editorial board of a variety of scientific journals such as “Cancer”, “Journal of Biological Chemistry”, “Cancer Biology and Therapy”, “Cell Cycle”, “Journal of Translational Medicine”. Dr. Zeng received his MD from Hengyang Medical College and PhD from Sun Yat-sen University. From 1992 to 1997 he conducted cancer research in Japan and America before returning to China.

Jing Ma (Secretary-General)

MD, PhD, Associate Professor, Brigham & Women’s Hospital, Harvard Medical School and Harvard T.H. Chan School of Public Health, USA

As a population scientist, Professor Ma studies cancer etiology, and specializes in prediction, prevention, and intervention. She served as a principal investigator and co-principal investigator of many well-endowed research funds, served as a peer reviewer for the National Institute of Health and for the Department of Defense grants review panel, and editor or reviewer for several top medical journals. Dr. Ma had served as the co-principal investigator of the Harvard School of Public Health project, “Advancing Breast Cancer Awareness and Prevention in China”. She is a visiting professor at Peking Union Medical School Hospital and at Shanghai Huashan Hospital. Dr. Ma is the author and co-author of over 170 peer review publications in top scientific journals. Dr. Ma also works closely with colleagues at the Harvard School of Public Health “China Initiative”, mentoring Chinese visiting scholars, organizing the executive training for China health policy makers and hospital CEOs, planning the U.S.-China Health Summit, and conducting applied research in China.


Steven Wu

MD, FASN, Director of Interventional Nephrology at Massachusetts General Hospital, Harvard Medical School, USA

Dr. Wu is the Director of Interventional Nephrology at Massachusetts General Hospital, and Assistant Professor of Medicine at Harvard Medical School. He serves as a member of leadership council at MGH Institute for Heart, Vascular and Stroke Care. He is the councilor at American Society of Diagnostic and Interventional Nephrology (ASDIN) and served as the Chairs at the 7th and 8th annual ASDIN scientific meetings. He is also the councilor of Chinese American Society of Nephrology. As a leader in his field and a physician with clinical training background both in China (Peking Union Medical College Hospital) and in US (Massachusetts General Hospital, Harvard Medical School), Dr. Wu has a passion for medical and educational exchange programs between two countries. He is running a MGH educational program of Interventional Nephrology for China, and is also a medical director for WorldCare - the pioneer & leader in global e-health services and solutions.

Olivia Ho. Cheng (Treasurer)

Co-founder of BE Healthcare Fund, USA

BE Healthcare Fund was established to invest in healthcare companies in countries with high growth and demand for quality healthcare services and products. Between 2003-2013, Olivia served as the President and CEO of a Massachusetts medical technology company - Aurora Imaging Technology, Inc., with cutting edge MRI system for breast cancer detection and diagnosis. Prior to coming to Aurora, Olivia has extensive commercial and investment banking experience, including being a Dedicated Authority Lender for Export-Import Bank of the United States and served as a member in White House Export Committee and co-founder of Pacific Republic Capital, a healthcare fund focused on investment in medical technology companies in the US. Olivia received her Master Degree in Economics from UCLA and Bachelor Degree from Taiwan National Chengchi University. Olivia has also been active in serving the following world renowned non-for-profit healthcare organizations: • Kenneth B. Schwartz Center (“SKC”), a non-profit organization headquartered at Massachusetts General Hospital in Boston since 2006; • Britton Chance Center for Biomedical Photonics National Laboratory at Huazhong University of Science and Technology (HUST) in Wuhan, China since 2008 and • Tufts Medical Center (TMC) in Boston. TMC is one of the top ranking medical centers in the United States and the principal teaching hospital. •Tufts University School of Medicine is a leading U.S. medical school, located in the famous medical education and research center of Boston. The school does pioneering research and has an exciting and modern curriculum for teaching medical students and other health care professionals— including public health students and physician assistant students.

Lan Xue

PhD, Cheung Kong Chair Professor and Dean of School of Public Policy and Management at Tsinghua University, Beijing, China

Dr. Lan Xue is a Cheung Kong Chair Professor and Dean of School of Public Policy and Management at Tsinghua University. With a PhD in public policy from Carnegie Mellon University in 1991, he taught at the George Washington University before returning back to China in 1996. His teaching and research interests include public policy analysis and management, science and technology policy, and crisis management. He has published widely in these areas.   He also serves as an adjunct professor at Carnegie Mellon University and a Non-Resident Senior Fellow of Brookings Institution. His many public service appointments include a member of the Expert Committee on Emergency Management of the State Council of China, Vice President of China Association of Public Administration, Vice Chairman of the National Steering Committee for MPA Education, a member of the Visiting Committee for Harvard Kennedy School, the Academic Advisory Board for the Blanvanik School of Government at Oxford University, and the Governing Board of International Development Research Center (IDRC). Since 2012, he has been the Co-Chair of the Leadership Council of the UN Sustainable Development Solution Network (UNSDSN). He is a recipient of the Fudan Distinguished Contribution Award for Management Science.

William Kirby

PhD, Distinguished Service Professor, T. M. Chang Professor of China Studies and Spangler Family Professor of Business Administration, Harvard University, USA

Dr. Kirby serves as Chairman of the Harvard China Fund and served as the Director of the Fairbank Center of Chinese Studies from 2006-2013. Before coming to Harvard in 1992, he was Professor of History, Director of Asian Studies, Dean of University College at Washington University in St. Louis. At Harvard, he served as Chair of the History Department, Director of the Harvard University Asia Center, and Dean of Faculty Arts and Sciences. As Dean, he led Harvard’s largest school, with 10,000 students, 1,000 faculty members, 2,500 staff and an annual budget of 1$ billion. He is currently an honorary professor at Honor Professor at Peking University; Nanjing University; Fudan University; Zhejiang University; Chongqing University; East China Normal University; Shanghai Academy of Social Sciences; National Chengchi University .

Yuanli Liu

PhD, Professor and Dean of Peking Union School of Public Health (PUSPH), Beijing, China; Founding Director of Harvard T.H. Chan School of Public Health (HSPH) China Initiative, Boston, USA

Before he was invited by the Peking Union Medical College as a member of the China “Thousand Talent” and to serve as the Dean of PUSPH, Dr. Liu served on the faculty of the Department of Global Health and Population at Harvard School of Public Health. Since 2005, Dr. Yuanli Liu has been the founding director of the HSPH China Initiative, which aims at helping advance health and social development in China through applied research studies, regular policy dialogues and educational programs for senior Chinese health executives at Harvard and for Harvard students in China. Dr. Liu currently remains as an adjunct professor of Global Health at the HSPH and is also an adjunct Professor of Health Policy and Management at Tsinghua University School of Public Policy and Management. Dr. Liu has been teaching and conducting research at Harvard in the areas of health policy and health system analysis since 1994, and has been involved in many research, training and policy consultation work in a number of African and Asian countries. He served on the Expert Committee of Health Policy and Management and the Expert Committee on Healthy China 2020, both of which were established by the Chinese Ministry of Health to help develop strategies for China to deal with major infectious as well as non-communicable diseases. Dr. Liu also served on the United Nations Millennium Development Taskforce on HIV/AIDS, Malaria, TB, and Access to Basic Medicines. He consulted for many international agencies including the World Bank, Asian Development Bank, UNDP, UNICEF, WHO.

John Quelch

DBA, MS, Charles Edward Wilson Professor of Business Administration, Harvard Business School, Professor in Health Policy and Management, Harvard T.H. Chan School of Public Health, USA

Between 2011 and 2013, Professor Quelch was Dean, Vice President and Distinguished Professor of International Management at CEIBS, China's leading business school. Between 2001 and 2011, he was the Lincoln Filene Professor of Business Administration and Senior Associate Dean at Harvard Business School, teaching Marketing in the Advanced Management Program. He served as Dean of London Business School from 1998 to 2001. Prior to 1998, he was the Sebastian S. Kresge Professor of Marketing and Co-Chair of the Marketing Unit at Harvard Business School. Professor Quelch is known for his teaching materials and innovations in pedagogy.  Over the past twenty-five years, his case studies have sold over 4 million copies, third highest in HBS history.  In 1995, he developed the first HBS interactive CD-ROM exercise (on Intel's advertising budgeting process). In 1999, he developed and presented a series of twelve one hour programs on Marketing Management for the Public Broadcasting System. Professor Quelch is currently developing a course on the role and responsibilities of corporations in solving public health problems, both in the United States and worldwide. Dr. Quelch is also a fellow of the Harvard China Fund, a Member of the Harvard China Advisory Board and Associate in Research at the Fairbank Center for Chinese Studies.

Feng Deng

Founder and CEO, Northern Light Venture Capital, Beijing, China

Mr. Feng Deng serves as a Founding Managing Director at Northern Light Venture Capital and co-founded it in 2005. Mr. Deng serves as an Advisor of Jeda Technologies Inc. He has more than 20 years of technical and managerial experience in the computer, communication, and data networking industries. Mr. Deng is Co-Founder of Hua Yuan Science and Technology Association and serves as its Director. Earlier from 2004 to 2005, he served as a Vice President of Corporate Strategy ... Northern Light Venture Capital (“NLVC”) is a venture capital firm targeting early and early growth stage opportunities in China. NLVC’s mission is “to partner with world-class entrepreneurs to build world-class companies”. Founded in 2005, NLVC has emerged as a top venture capital firm with the rapidly growing Chinese economy. NLVC manages approximately US$ 500 million in committed capital with 2 US$ funds and 2 RMB funds. With the leading institutional investors NEA and Greylock as the anchor investors, NLVC has the world-class LPs and the top fund of funds from China as well. NLVC’s investment strategy emphasizes: Early and early growth stage, China concept, and innovative business model or high tech driven opportunity. NLVC seeks innovative businesses models or high-tech driven investment opportunities that leverage China’s market, economic, or human resource advantages to build exceptional, lasting enterprises in the global economy.


William Haseltine

MD, PhD, ACCESS Health International founder and chairman, USA

William A. Haseltine PhD has an active career in both science and business. He was a professor at Harvard Medical School and Harvard School of Public Health from 1976-1993 where he was Founder and the Chair of two academic research departments. He is well known for his pioneering work on cancer, HIV/AIDS and genomics. He has authored more than 200 manuscripts in peer-reviewed journals and is the author of several books. He is the Founder of Human Genome Sciences, Inc and served as the Chairman and CEO of the Company until 2004. He is also the Founder of several other successful biotechnology companies. Companies he has founded account for five drugs currently on the market including Benlysta and ABTRAX (Human Genome Sciences,Inc), Velcade (Proscript/Leucocyte,Inc), and Provenge (Dendreon,Inc).  William Haseltine is currently Chairman and President of ACCESS Health International, Inc ( that supports access to affordable, high quality health services in low, middle and high income countries, and Chairman Haseltine Foundation for Science and the Arts that fosters a dialog between sciences and the arts. He is an advisor to several governments, biotechnology and pharmaceutical companies. He is a member of the Advisory Board of the IE University, Madrid, the Advisory Council for the Koch Institute of MIT and the Life Sciences Foundation, a member of the Advisory Boards of the Ragon Institute , The Rockefeller University Council, and The FXB Center for Health and Human Rights at the Harvard School of Public health. He is a Lifetime Governor of the New York Academy of Sciences and a member of the Board of AID for AIDS International. He is an honorary member of the Board of Trustees of the Brookings Institution, a member of the Council on Foreign Relations,  He is a member of the Advisory Board of the Metropolitan Opera, New York, a member of the Chairman’s Council of the Metropolitan Museum, New York, a Member of the International Council of the Guggenheim Museum, The International Council of The Tate Modern, a Member of Board of Directors of the Young Concert Artists, Inc. and the Youth Orchestra of the Americas, The American Friends of the Budapest Orchestra, and the China Arts Foundation.

Zhen Jiao

President, CDH Investments, Beijing, China

Mr. Jiao graduated from Shandong University (山東大學) with a bachelor of mathematics in July 1986, and obtained his master’s degree in engineering from the PRC Ministry of Aerospace Industry in October 1989. Mr. Jiao was a researcher in the China Aerospace Service and Technology Corporation (中國航天科技集團公司第710研究所) from August 1989 to January 1995. He served as the vice-general manager of the direct investment department of China International Capital Corporation Ltd. (中國國際金融有限公司) from December 1995 to August 2002. Since 2002, he has been the President of CDH Investments. A spinoff from Chinese investment bank China International Capital Corp., CDH started in 2002 with nine people, led by Mr. Wu (Chairman). It now has US$14 billion in assets under management and has ambitions to be the go-to Chinese manager of more than just private-equity investments. Already, private equity accounts for just three-quarters of its business, with the rest coming from investing in publicly listed stocks, real estate, mezzanine finance and venture capital.